S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Ruptured oil pipeline off California approved for repairs
Italy's Meloni vows to put national energy interests first
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
Danes: Nord Stream 2 pipeline seems to have stopped leaking
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Ruptured oil pipeline off California approved for repairs
Italy's Meloni vows to put national energy interests first
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
Danes: Nord Stream 2 pipeline seems to have stopped leaking
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Ruptured oil pipeline off California approved for repairs
Italy's Meloni vows to put national energy interests first
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
Danes: Nord Stream 2 pipeline seems to have stopped leaking
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Ruptured oil pipeline off California approved for repairs
Italy's Meloni vows to put national energy interests first
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
Danes: Nord Stream 2 pipeline seems to have stopped leaking
NYSE:ATNM

Actinium Pharmaceuticals - ATNM Stock Forecast, Price & News

$7.38
+0.18 (+2.50%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.11
$7.63
50-Day Range
$4.81
$8.48
52-Week Range
$4.41
$9.21
Volume
134,650 shs
Average Volume
175,977 shs
Market Capitalization
$185.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

Actinium Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
116.8% Upside
$16.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.22) to ($1.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.45 out of 5 stars

Medical Sector

1042nd out of 1,095 stocks

Pharmaceutical Preparations Industry

516th out of 547 stocks

ATNM stock logo

About Actinium Pharmaceuticals (NYSE:ATNM) Stock

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATNM Stock News Headlines

See More Headlines
Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATNM Company Calendar

Today
10/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+116.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,770,000.00
Net Margins
-2,202.18%
Pretax Margin
-2,202.18%

Debt

Sales & Book Value

Annual Sales
$1.14 million
Book Value
$3.34 per share

Miscellaneous

Free Float
24,858,000
Market Cap
$185.83 million
Optionable
Optionable
Beta
0.24

Key Executives

  • Mr. Sandesh C. Seth M.B.A. (Age 58)
    M.S., MBA, Chairman & CEO
    Comp: $1.04M
  • Mr. Steven O'Loughlin BS (Age 36)
    CFO & Corp. Sec.
    Comp: $520k
  • Dr. Paul Diamond Esq.
    Ph.D., VP of Patent & Legal Counsel
  • Dr. David Gould
    Sr. VP of Corp. Devel. & Corp. Affairs
  • Dr. Bernie Cunningham
    Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
  • Dr. Qing Liang
    VP & Head of Radiation Sciences
  • Dr. Robert N. Daly M.S.
    Ph.D., VP & Head of Clinical Operations
  • Dr. Mamata Gokhale
    VP & Global Head of Regulatory Affairs
  • Dr. Avinash Desai M.D.
    Chief Medical Officer
  • Dr. Arun Swaminathan Ph.D.
    Chief Bus. & Commercial Officer













ATNM Stock - Frequently Asked Questions

Should I buy or sell Actinium Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATNM shares.
View ATNM analyst ratings
or view top-rated stocks.

What is Actinium Pharmaceuticals' stock price forecast for 2022?

1 Wall Street research analysts have issued 12-month price targets for Actinium Pharmaceuticals' stock. Their ATNM share price forecasts range from $16.00 to $16.00. On average, they expect the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 116.8% from the stock's current price.
View analysts price targets for ATNM
or view top-rated stocks among Wall Street analysts.

How have ATNM shares performed in 2022?

Actinium Pharmaceuticals' stock was trading at $5.41 on January 1st, 2022. Since then, ATNM shares have increased by 36.4% and is now trading at $7.38.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Actinium Pharmaceuticals own?
What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "ATNM."

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $7.38.

How much money does Actinium Pharmaceuticals make?

Actinium Pharmaceuticals (NYSE:ATNM) has a market capitalization of $185.83 million and generates $1.14 million in revenue each year.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 MADISON AVENUE 7TH FLOOR, NEW YORK NY, 10016. The official website for the company is www.actiniumpharma.com. The company can be reached via phone at 646 677 3870 or via email at investorrelations@actiniumpharma.com.

This page (NYSE:ATNM) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.